REG - RTW Biotech Opp. - Amani closes $25 million Series A financing

RTW Biotech OpportunitiesAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260331:nRSe7051Ya&default-theme=true

RNS Number : 7051Y  RTW Biotech Opportunities Ltd  31 March 2026

LEI: 549300Q7EXQQH6KF7Z84

31 March 2026

RTW Biotech Opportunities Ltd

Amani closes $25 million Series A financing

·      RTW new company creation, with proceeds to advance lead program
AM-01 for schizophrenia

·      In-licensed worldwide rights to Phase 3-ready component of AM-01

·      RTW Bio's investment represents 0.8% of NAV as at 28 February
2026

RTW Biotech Opportunities Ltd (the "Company" or "RTW Bio"), the London Stock
Exchange-listed investment company focused on identifying transformative
assets with high growth potential across the life sciences sector, is pleased
to the note the announcement by private portfolio company Amani Therapeutics
("Amani") of the completion of a $25 million Series A financing.

Amani is a biotechnology company focused on developing highly efficacious and
safer medicines for people living with serious neuropsychiatric disorders. RTW
Bio invested $6.6 million in the Series A financing (in addition to $0.4
million invested in a previous SAFE funding that later converted to Series A
shares), the total investment representing 0.8% of NAV as of 28 February 2026.
Amani is the sixth new company creation of RTW Investments, LP.

Proceeds from the financing are expected to support the advancement of AM-01,
a product comprising clozapine and an in-licensed Phase 3-ready component.
AM-01 is designed to potentially deliver the efficacy of clozapine while
addressing its most significant safety liability, severe neutropenia, a
condition characterized by low levels of a type of neutrophils (white blood
cells) in the blood. Clozapine is the only therapy proven to meaningfully
improve symptoms in treatment-resistant schizophrenia and to reduce suicide
risk in patients with schizophrenia and schizoaffective disorder. However, its
use remains limited due to safety concerns and the requirement for regular
blood monitoring.

 

Rod Wong, CIO of RTW Investments, said, "We are pleased to support Amani
Therapeutics in its mission to advance innovative treatments for
neuropsychiatric disorders. The development of AM-01 represents a meaningful
step forward towards addressing the significant unmet need in schizophrenia,
and we believe Amani's approach has the potential to transform the standard of
care."

 

Amani's announcement can be found here
(https://amanitx.com/press-release/amani-therapeutics-closes-25-million-series-a-to-advance-am-01-a-potential-best-in-class-therapy-for-serious-neuropsychiatric-disorders/)
.

 

Enquiries:

 RTW Investments, LP - Investment Manager  +44 (0)20 7959 6362

 Oliver Kenyon                             biotechopportunities@rtwfunds.com

 Krisha McCune (Investor Relations)

 Cadarn Capital - PR & IR Partner

 Lucy Clark (PR)                           +44 (0)7984 184 461 / lucy@cadarncapital.com

 David Harris (Distribution)               +44 (0)7368 883 211 / david@cadarncapital.com

 Deutsche Numis - Joint Corporate Broker   +44 (0)20 7260 1000

 Nathan Brown

 Duncan Monteith

 George Shiel

 BofA Securities - Joint Corporate Broker  +44 (0)20 7628 1000

 Edward Peel

 Alex Penney

 Altum (Guernsey) Limited                  +44 (0)1481 703 100

 Joanna Duquemin Nicolle

 Sadie Morrison

 

About RTW Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on
identifying transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors. Driven by a long-term
approach to support innovative businesses, RTW Biotech Opportunities Ltd
invests in companies developing next-generation therapies and technologies
that can significantly improve patients' lives. RTW Biotech Opportunities Ltd
is managed by RTW Investments, LP, a leading healthcare-focused
entrepreneurial investment firm with deep scientific expertise and a strong
track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwbio.com
(https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/) for more
information.

 

***********

The information in this announcement may include forward-looking statements,
which are based on the current expectations and projections about future
events, and in certain cases can be identified by the use of terms such as
"may", "will", "should", "expect", "anticipate", "project", "estimate",
"intend", "continue", "target", "believe" (or the negatives thereon) or other
variations thereon or comparable terminology. These forward-looking
statements, as well as those included in any related materials, are subject to
risks, uncertainties and assumptions about the Company and/or its underlying
investments, including, among other things, the development of the applicable
entity's business, trends in its operating industry, expected use of financing
proceeds and future capital expenditures and acquisitions. In light of these
risks, uncertainties and assumptions, the events in the forward-looking
statements may not occur.

The information contained in this announcement is given at the date of its
publication (unless otherwise marked). No reliance may be placed for any
purpose whatsoever on the information or opinions contained in this
announcement or on its completeness, accuracy or fairness.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PFUEAXDEDFKKEFA



            Copyright 2019 Regulatory News Service, all rights reserved